Patents Examined by John M Mauro
  • Patent number: 11458132
    Abstract: The present invention is directed to compositions, methods and kits for treatment of cancer, e.g., hepatocellular carcinoma (HCC). In some embodiments, the present invention discloses the use of a small-molecule compounds of Formula (I) to inhibit tubulin acetylation, to inhibit cell migration, or to modulate cell compaction.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: October 4, 2022
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott Edward Schaus, Ulla Hansen, Emily Ann York, Niranjana Pokharel
  • Patent number: 11459301
    Abstract: The invention is directed to a novel crystalline S-apomorphine hydrochloride hydrate salt.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: October 4, 2022
    Assignee: Aclipse One, Inc.
    Inventor: Ning Shan
  • Patent number: 11447509
    Abstract: The present technology is directed to polypropionate lactone stereotetrads of Formula (I) (or a pharmaceutically acceptable salt and/or solvate thereof) which are significant intermediates for multiple synthetic applications.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: September 20, 2022
    Assignee: AKANOCURE PHARMACEUTICALS, INC.
    Inventors: Mohammad N. Noshi, Philip L. Fuchs
  • Patent number: 11446306
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: September 20, 2022
    Assignee: Zenith Epigenetics Ltd.
    Inventors: John Frederick Quinn, Bryan Cordell Duffy, Shuang Liu, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, Gregory Steven Wagner, Peter Ronald Young
  • Patent number: 11447477
    Abstract: Provided is a compound represented by formula (I). Also provided are a pharmaceutical composition containing the compound of formula (I) and use of the compound in preparing indoleamine-2,3-dioxygenase (IDO) inhibitor drugs. The compound or the pharmaceutical composition thereof can be used for preparing drugs for preventing and/or treating diseases having pathological features of IDO-mediated tryptophan metabolic pathways.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: September 20, 2022
    Assignee: HINOVA PHARMACEUTICALS INC.
    Inventors: Wu Du, Chaowu Ai, Yu Li, Kun Wen, Haibin Lv, Wen Ren, Jinyun He, Dekun Qin, Xinghai Li, Yuanwei Chen
  • Patent number: 11434230
    Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: September 6, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Manmohan Reddy Leleti, Rebecca M. Lui, Viengkham Malathong, Jay P. Powers, Rajinder Singh, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang
  • Patent number: 11434239
    Abstract: Aza-dihydro-acridone derivatives of formula I, wherein the meaning of R1, R?1, R2 and R3 is that specified in the description, to be used as T cells proliferation inhibitors.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: September 6, 2022
    Assignee: Artax Biopharma Inc.
    Inventors: Andrés Gagete Mateos, Damiá Tormo Carulla, Luc Marti Clauzel, Julio Castro Palomino
  • Patent number: 11434250
    Abstract: Compounds of Formula I and methods of use as Interleukin-1 Receptor Associated Kinase 4 (IRAK4) inhibitors are described herein.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: September 6, 2022
    Assignee: Genentech, Inc.
    Inventors: Marian C. Bryan, Joy Drobnick, James Richard Kiefer, Jr., Aleksandr Kolesnikov, Naomi S. Rajapaksa
  • Patent number: 11426402
    Abstract: Disclosed herein are compounds, their pharmaceutical salts, and pharmaceutical compositions that selectively activate the inositol-requiring enzyme 1 (IRE1)/X-box binding protein 1 (XBP1s) signaling pathway of the unfolded protein response (UPR), but that do not target the IRE1 kinase domain. The compounds are useful in treating diseases or conditions characterized by imbalances in proteostasis within the endoplasmic reticulum (ER) or secretory pathway, including those not associated with ER stress or activation of UPR.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: August 30, 2022
    Assignee: The Scripps Research Institute
    Inventors: R. Luke Wiseman, Jeffery W. Kelly, Julia M. D. Grandjean, Christina B. Cooley, Lars Plate, Enrique Saez, Aparajita Madhavan, Bernard Kok
  • Patent number: 11427598
    Abstract: The present invention relates spiro-cyclic amine derivatives of the formula (I) wherein R1; R2; R3; Q; —W-T-; R5; Z; and A have the definitions provided in the claims; or a pharmaceutically acceptable salt, a solvate or hydrate thereof or one or more N-oxides thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of diseases and conditions in which (a) S1P receptor(s) is(are) involved.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: August 30, 2022
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Axel Stoit, Wouter I. Iwema Bakker, Hein K. A. C. Coolen, Maria J. P. van Dongen, Nicolas J.-L. D. Leflemme, Adrian Hobson
  • Patent number: 11427596
    Abstract: Embodiments herein provide fused-pyrido heterocycles such as azaindoles, carboline derivatives, furo[b]pyridines or furo[b]pyridine-isatin hybrids of Formula I. Embodiments also relate to a process for a synthesis of variety of complex pyrido-heterocycles The pyrido-heterocycles can be used for treating cancer (cervix, kidney, lung, breast and epidermal skin) and multi-drug resistant tuberculosis. These heterocycles can also be used as anti-biofilm agents against pathogenic strains, which will minimize the risk of secondary infections.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: August 30, 2022
    Assignee: INDIAN INSTITUTE OF TECHNOLOGY INDORE
    Inventors: Venkatesh Chelvam, Premansh Dudhe, Mena Asha Krishnan, Avinash Sonawane
  • Patent number: 11419854
    Abstract: To provide an appropriate method of treatment with pemafibrate for a liver cirrhosis patient. The present invention relates to the use of pemafibrate in a liver cirrhosis patient. More particularly, the present invention relates to a regimen for administering a reduced dose of pemafibrate to a liver cirrhosis patient in need of treatment with pemafibrate than to persons with normal liver function.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 23, 2022
    Assignee: KOWA COMPANY, LTD.
    Inventors: Satoshi Kojima, Ryohei Tanigawa
  • Patent number: 11414387
    Abstract: Compounds of Formula I or pharmaceutically acceptable salts or esters thereof capable of binding to and modulating the activity of a stimulator of interferon genes (STING) protein are provided. Methods involving compounds of Formula I as effective modulators of STING are also provided.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: August 16, 2022
    Assignee: STINGTHERA, INC.
    Inventors: Brian T. Chamberlain, James M. Rice, Finith E. Jernigan, III, Woody Sherman, Meghana M. Kulkarni, Sharon Shechter, Bryce K. Allen, Dazhi Tan, Kristen A. Marino, Zhixiong Lin
  • Patent number: 11414401
    Abstract: This application discloses novel substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, prodrugs, and compositions thereof, which are useful for the treatment or prevention of diseases or medical conditions mediated by epidermal growth factor receptors (EGFRs), including but not limited to a variety of cancers.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: August 16, 2022
    Assignees: BETA PHARMA INC., BETA PHARMA (SHANGHAI) CO., LTD.
    Inventors: Jirong Peng, Michael John Costanzo, Michael Nicholas Greco, Michael Alan Green, Victoria Lynn Wilde, Don Zhang
  • Patent number: 11407768
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: August 9, 2022
    Assignee: KALLYOPE, INC.
    Inventors: Iyassu Sebhat, Shuwen He
  • Patent number: 11401279
    Abstract: The present disclosure is directed to compounds of Formula (I): which modulate PD-1/PD-L1 protein/protein interaction, compositions, and methods of treating various diseases, including infectious diseases and cancer.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: August 2, 2022
    Assignee: Incyte Corporation
    Inventors: Jingwei Li, Liangxing Wu, Wenqing Yao
  • Patent number: 11396517
    Abstract: Provided are compounds of Formula (I), pharmaceutical compositions comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: July 26, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Xuedong Dai, Olivier Alexis Georges Querolle, Daniel Jason Krosky, Wei Cai, Liqiang Fu, Linglong Kong, Yingtao Liu, Zhao-Kui Wan, Barbara Morschhäuser Geb. Herkert, Vineet Pande, James Patrick Edwards, Aaron Nathaniel Patrick, Patrick René Angibaud, Virginie Sophie Poncelet
  • Patent number: 11390599
    Abstract: Compounds that may selectively inhibit Oplophorus luciferase-derived bioluminescent complexes, e.g., NanoBiT® bioluminescent complex, are disclosed as well as compositions and kits comprising the compounds, and methods of using the compounds.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: July 19, 2022
    Assignee: Promega Corporation
    Inventors: Joel R. Walker, Mary Hall, Christopher Todd Eggers, Horacio Lazaro
  • Patent number: 11382914
    Abstract: An object of the present invention is to provide pharmaceutical agents that reduce risk for decrease in bone mineral density due to their effect of reducing estrogen levels and exert excellent therapeutic effects on endometriosis. The present invention relates to pharmaceutical compositions for treating endometriosis comprising 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid or a pharmaceutically acceptable salt thereof, which are administered orally once a day at a daily dose of between 50 mg and 75 mg calculated as a free form.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: July 12, 2022
    Assignee: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Takuro Dan, Hideomi Takahashi, Yu Kuramochi
  • Patent number: 11377422
    Abstract: The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: July 5, 2022
    Assignee: Nocion Therapeutics, Inc.
    Inventors: Bridget McCarthy Cole, James Lamond Ellis